Myeloproliferative Neoplasms

Expert faculty review and share their insights on key findings in myelodysplastic neoplasms presented at the 2023 ASH Annual Meeting.

Share

Program Content

Activities

  • MPN Updates 2023
    Conference to Clinic: Myeloproliferative Neoplasm Updates 2023
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 11, 2024

  • ASH 2023: MPNs
    Key Studies in Myeloproliferative Neoplasms: Independent Conference Coverage of ASH 2023
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 06, 2024

    Expires: March 05, 2025

Activities

TRANSFORM 1
TRANSFORM-1: Phase III Trial of Navitoclax + Ruxolitinib vs Placebo + Ruxolitinib in Previously Untreated Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

RuxoBEAT
RuxoBEAT: Interim Results From a Randomized Phase IIb Study of Ruxolitinib Vs BAT as First-line Therapy in High-Risk Polycythemia Vera
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

Bomedemstat in ET
Phase IIb Trial of LSD1 Inhibitor Bomedemstat in Patients With Essential Thrombocythemia Resistant or Intolerant to Standard Therapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2023

MANIFEST 2
MANIFEST-2: Phase III Trial of Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib for JAK Inhibitor–Naive Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

Bomedemstat Plus Ruxolitinib for MF
Phase II Study of Bomedemstat Plus Ruxolitinib for Patients With Myelofibrosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

Faculty

cover img faculity

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.